November 18, 2022

MultiplexDX supported Talent BMC SAV Award which recognizes the best young talented scientists

MultiplexDX decided to dedicate its share from the sale of RT-PCR tests to the TALENT BMC SAV AWARD program launched by the Biomedical Research Center of the Slovak Academy of Sciences. Our CEO, Pavol Cekan, accepted the offer to become the chairman of the selection board. The credit for this beautiful idea goes to Boris Klempa and his team. The award aims to support young talented scientists and their research. Keeping young talent is one of the keys to success, not only in science.

This year’s winners are RNDr. Viktória Čabanová, PhD., Mgr. Lenka Tomášová, PhD.,Mgr. Jana Plavá, Ph.D. We are looking forward to the next year’s nominations!

About MultiplexDX

MultiplexDX is one of the most innovative biotech corporations, created to bring its revolutionary technologies to the market of personalized molecular diagnostics. The company has representation in both U.S. and European markets. The collaborators of MultiplexDX are from the world’s most prestigious scientific organizations including the National Cancer Institute, Rockefeller University, Albert Einstein University, Vanderbilt University, Cornell University, Queens University (Canada), Hebrew University of Jerusalem (Israel), and the Max Delbrück Center for Molecular Medicine (Germany).

MultiplexDX IP-based and innovative platform merges histopathology methods, biomarker quantification, visualization and gene expression with a single-cell resolution by combining MDX proprietary visual and sequencing technologies into one diagnostic test. This cross-validation approach eliminates diagnostic errors and creates 100% precise cancer profiling for each patient which allows clinicians to suggest specific, personalized cancer treatment.

Find out more about MultiplexDX on Corporate website, Facebook, LinkedIn, Twitter

Other latest

MultiplexDX News